Canature Health Technology Group Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, without false records, misleading statements, or significant omissions.
On June 3, 2026, the Company held the 2025 Annual General Meeting to elect the seventh Board of Directors, which, together with the employee representative directors elected at the first employee representative assembly of 2026, constitutes the seventh Board of Directors of the Company. On the same day, the Company convened the first meeting of the seventh Board of Directors, where the following proposals were reviewed and approved:
- Proposal on the Election of the Chairman of the Seventh Board of Directors
- Proposal on the Election of the Vice Chairman of the Seventh Board of Directors
- Proposal on the Election of Members of Various Special Committees of the Seventh Board of Directors
- Proposal on the Appointment of the General Manager
- Proposal on the Appointment of Other Senior Management Personnel
- Proposal on the Appointment of the Secretary of the Board and Securities Affairs Representative
The relevant information is hereby announced as follows:
I. Composition of the Seventh Board of Directors
- Chairman: Mr. Qu Jianguo
- Non-independent Directors: Mr. Qu Jianguo, Mr. Qu Yaming, Ms. JIN FENG
- Independent Directors: Mr. Zhu Zhenyu, Mr. Hou Yubo
All members of the seventh Board of Directors (resumes attached) possess the qualifications to serve as directors of a listed company, have not been penalized by the China Securities Regulatory Commission or other relevant departments, and are not subject to any prohibitions as stipulated in the Company Law, Articles of Association, or the Shenzhen Stock Exchange's self-regulatory guidelines. The number of senior management personnel concurrently serving as directors does not exceed half of the total number of directors, and the proportion of independent directors is not less than one-third of the total number of directors. The term of the seventh Board of Directors is three years, starting from the date of approval by the 2025 Annual General Meeting, i.e., June 3, 2026.
II. Composition of Various Special Committees of the Seventh Board of Directors
According to the provisions of the Company Law, Articles of Association, and the working rules of the special committees of the Board of Directors, the members of each special committee are as follows:
| Committee Name | Committee Members | Committee Chair (Convener) |
|---|---|---|
| Strategic Committee | Qu Jianguo, Qu Yaming, Hou Yubo | Qu Jianguo |
| Audit Committee | Zhu Zhenyu, Hou Yubo, Qu Jianguo | Zhu Zhenyu |
| Compensation and Assessment Committee | Hou Yubo, Zhu Zhenyu, Qu Yaming | Hou Yubo |
| Nomination Committee | Hou Yubo, Zhu Zhenyu, Qu Jianguo | Hou Yubo |
The term of the above special committee members is three years, starting from the date of approval by the first meeting of the seventh Board of Directors, i.e., June 3, 2026.
III. Appointment of Senior Management Personnel and Securities Affairs Representative
- General Manager: Mr. Qu Yaming
- Deputy General Manager: Ms. JIN FENG
- Chief Financial Officer: Mr. Liu Wenjun
- Secretary of the Board: Mr. Xu Yanmao
- Securities Affairs Representative: Ms. Lu Dongying
The term of the above senior management personnel is three years, starting from the date of approval by the first meeting of the seventh Board of Directors, i.e., June 3, 2026. After review by the Company's Board of Directors' Audit Committee and Nomination Committee, it is confirmed that all senior management personnel meet the qualifications required by laws and regulations for senior management of listed companies, and there are no circumstances that prohibit them from serving as senior management personnel as stipulated in the Company Law and Articles of Association. They have not been identified as market entry bans by the China Securities Regulatory Commission and have not been penalized by the China Securities Regulatory Commission or other relevant departments, and are not subject to any dishonesty enforcement.